FDA orders ‘black box’ warning for antipsychotic drugs

Share this article:
The FDA has issued a public health advisory concerning the use of antipsychotic drugs after finding that elderly patients taking the medications were more likely to die than those receiving a placebo.
The agency said it would require manufacturers of the drugs to place "black box warnings" -- the FDA's most severe -- on the labels of all of the drugs.
The advisory applies to drugs including Bristol-Myers Squibb's Abilify, Eli Lilly's Symbyax and Zyprexa, AstraZeneca's Seroquel, Johnson & Johnson's Risperdal, Novartis' Clozaril and Pfizer's Geodon.
The FDA said patients receiving these drugs for treatment of behavioral disorders associated with dementia should have their treatment reviewed by their healthcare providers.
In analyses of 17 placebo-controlled studies of four drugs in the atypical antipsychotic class, the rate of death for elderly patients with dementia was about 1.6 to 1.7 times that of placebo. Although the causes of death were varied, most seemed to be either heart-related or from infections like pneumonia.
Atypical antipsychotics fall into three drug classes based on their chemical structure. Because the increase in mortality was seen with atypical antipsychotic medications in all three chemical classes, the agency has concluded that the effect is probably related to the common pharmacologic effects of all atypical antipsychotic medications, including those that have not been studied in the dementia population.
The agency is also considering adding a warning to the labeling of older antipsychotic medications because limited data also suggest a similar increase in mortality for these drugs. The review of the data on the older drugs is still on-going, the FDA said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.